Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Jul 1;54(3):285–289. doi: 10.1097/QAI.0b013e3181bf648a

Figure 1.

Figure 1

Oral clearance rate (CL/F, L/h/m2) for nelfinavir in children with the CYP2C19-681G>A genotypes in each race/ethnicity. Each circle represents nelfinavir CL/F in each subject with the CYP2C19-681-G/G (left), -G/A (heterozygous, middle), and -A/A (homozygous, right) in each race/ethnicity. The lines in the middle represent the median of CL/F for NFV.